Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds

Chemical Research in Toxicology

Volumn 25, Issue 10, 2012, Pages 2067-2082

  Sakatis, Melanie Z ^a   Reese, Melinda J ^b   Harrell, Andrew W ^a   Taylor, Maxine A ^a   Baines, Ian A ^a   Chen, Liangfu ^b   Bloomer, Jackie C ^a   Yang, Eric Y ^b   Ellens, Harma M ^b   Ambroso, Jeffrey L ^b   Lovatt, Cerys A ^a   Ayrton, Andrew D ^a   Clarke, Stephen E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 BUTYRYL 7 METHOXYCOUMARIN; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHYLAMINOETHYL 7 METHOXYCOUMARIN; 7 BENZYLOXYQUINOLINE; 7 METHOXY 4 TRIFLUOROMETHYLCOUMARIN 3 ACETIC ACID; ALLOPURINOL; ALPIDEM; AMINOPHENAZONE; AMINOSALICYLIC ACID; AMIODARONE; AMITRIPTYLINE; AMODIAQUINE; AMPHOTERICIN B; AMSACRINE; ATORVASTATIN; AZATHIOPRINE; AZITHROMYCIN; BENZBROMARONE; BROMFENAC; BUSULFAN; CARBAMAZEPINE; CARBIMAZOLE; CARMUSTINE; CYTOCHROME P450; DIETHOXYFLUORESCEIN; ETHOXYRESORUFIN; GLUTATHIONE; PARACETAMOL; RADIOISOTOPE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DECISION MAKING; DRUG ACTIVITY; IN VITRO STUDY; LIVER TOXICITY; TOXIC HEPATITIS;

CYTOCHROME P-450 ENZYME SYSTEM; DECISION TREES; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; DRUG-INDUCED LIVER INJURY; GLUTATHIONE; HUMANS; LIVER; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING;

EID: 84867504514     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx300075j     Document Type: Article

References (44)

1. Ballet, F. (1997) Hepatotoxicity in drug development: detection, significance and solutions J. Hepatol. 26, 26-36
2. Friedman, S. E., Grendell, J. H., and McQuaid, K. R. (2003) Current Diagnosis and Treatment in Gastroenterology, pp 664-679, Lang Medical Books, New York.
3. McNally, P. F. (2006) GI Liver Secrets, C. V. Mosby, Saint Louis, MS.
4. Antoine, D. J., Williams, D. P., and Park, B. K. (2008) Understanding the role of reactive metabolites in drug-induced hepatotoxicity: state of the science Expert Opin. Drug Metab. Toxicol. 4, 1415-1427
5. KMR Pharmaceutical Benchmarking Forum, R & D General Metrics Study Presentation, 4 May 2006.
6. Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., and Lemasters, J. J. (2002) Mechanisms of heptotoxicity Toxicol. Sci. 65, 166-176
7. Uetrecht, J. (2008) Idiosyncratic drug reactions: past, present and future Chem. Res. Toxicol. 21, 84-92
8. Masubuchi, Y. and Horie, T. (2007) Toxicological significance of mechanism-based inactivation of cytochrome P450 enzymes by drugs Crit. Rev. Toxicol. 37, 389-412
9. Kalgutkar, A. S., Obach, R. S., and Maurer, T. S. (2007) Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse reactions Curr. Drug Metab. 8, 407-447
10. Matzinger, P. (1994) Tolerance, danger and the extended family Annu. Rev. Immunol. 12, 991-1045
11. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development Chem. Res. Toxicol. 17, 3-16
12. Obach, S. R., Kalgutkar, A. S., Soglia, J. R., and Zhao, S. X. (2008) Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from non-heptatotoxix drugs? An analysis of 18 drugs with consideration of intrinsic clearance and dose Chem. Res. Toxicol. 21, 1814-1822
13. Bauman, J. N., Kelly, J. M., Tripathay, S., Zhao, S. X., Lam, W. W., Kalgutkar, A. S., and Obach, R. S. (2009) Can In vitro metabolism-dependent covalent binding data distinguish hepatotoxic and non-hepatotoxic drugs? An analysis using Human Hepatocytes and liver s-9 fraction Chem. Res. Toxicol. 22, 332-340
14. Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., and Okazki, O. (2009) A zone classification systemi for risk assessment of idiosyncratic toxicity using daily dose and covalent binding Drug Metab. Dispos. 37, 1970-1977
15. Gan, J., Qian, R., Bing, H., Mingshe, Z., and Wen, C. S. (2009) In vitro screening of 50 highly prescribed drugs for thiol adduct formation - comparison of potential for drug-induced toxicity and extent of adduct formation Chem. Res. Toxicol. 22, 690-698
16. Usui, T., Mise, M., Hashizume, T., Tabuki, M., and Komuro, S. (2009) Evaluation of the potential of drug-induced liver injury based on in vitro covalent binding to human liver protein Drug. Metab. Dispos. 37, 2383-2392
17. Nakayama, S., Takakusa, H., Watanabe, A., Miyaji, Y., Suzuki, W., Sugiyama., D., Shiosakai, K., Honda, K., Okudaira, N., Izumi, T., and Okazaki, O. (2011) Combination of glutathione trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites Drug Metab. Dispos. 39, 1247-1254
18. Sawamura, R., Okudaira, N., Watanabe, K., Murai, T., Kobayashi, Y., Tachibana, M., Ohnuki, T., Masuda, K., Honma, H., Kurihara, A., and Okazaki, O. (2010) Predictability of idiosyncratic drug toxicity risk for carboxylic acid-containing drugs based on the chemical stability of acyl glucuronide Drug Metab. Dispos. 38, 1857-1864
19. Stepan, A. F., Walker, D. P., Bauman, J., Price, D. A., Baillie, T. A., Kalgutkar, A. S., and Aleo, M. D. (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States Chem. Res. Toxicol. 24, 1345-1410
20. Reese, M., Sakatis, M., Harrell, A., Yang, E., Chen, L., Taylor, M., Baines, I., Zhu, L., Ayrton, A., and Clarke, S. (2011) An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development Chem.-Biol. Interact. 192, 60-64
21. Allen, J., Jeffrey, P., Williams, R., and Ratcliffe, A. J. (2010) Approaches to assessing drug safety in the discovery phase. Highlights of the Society for Medicines Research Symposium held on September 24th, 2009, at the National Heart & Lung Institute, Kensington, London. U.K Drugs Future 35, 67-75
22. Bambal, R. B. and Elliott, R. L. (2000) 7-Alkoxycoumarins as CYP2C9 Substrates, International Patent Number WO 00/22159.
23. Bloomer, J. C. and Leach, C. A. (2002) Enzyme Substrate, International Patent Number WO 02/12542 A2.
24. Clarke, S. E. (1999) 7-Alkoxycoumarins as Cytochrome P450 Substrates, International Patent Number WO 99/58710.
25. Bambal, R. and Bloomer, J. C. (2001) Enzyme Subsrate, International Patent Number WO 01/44495 A2.
26. Biour, M., Poupon, R., Grange, J. D., and Chazouilleres, O. (2000) Hepatotoxicity of drugs Gastroenterol. Clin. Biol. 24, 1052-1091
27. Physician's Desk Reference (PDR), Thomson Corporation, Toronto, Canada.
28. DailyMed, U.S. National Library of Medicine, National Institutes of Health, Health & Human Services.
29. PharmaPendium (2010) Elsevier Properties SA, Switzerland.
30. Shardlow, C., Generaux, G., MacLauchlin, C., Pons, N., Skordos, K., and Bloomer, J. (2011) Utilising drug-drug interaction prediction tools during drug development: enhanced decision-making based on clinical risk Drug Metab. Dispos. 39, 2076-2084
31. Park, B. K., Boobis, A., Clarke, S., Goldring, C. E. P., Jones, D., Kenna, J. G., Lambert, C., Laverty, H. G, Naisbitt, D., Nelson, S., Nicoll-Griffith, D. A., Obach, R. S., Routledge, P., Smith, D. A., Tweedie, D. J., Vermeulen, N., Williams, D. P., Wilson, I. D., and Baillie, T. A. (2011) Managing the challenge of chemically reactive metabolites in drug development Nat. Rev. Drug Discovery 10, 292-306
32. Thompson, R. A., Isin, E. M., Li, Y., Weaver, R., Weidolf, L., Wilson, I., Claesson, A., Page, K., Dolgos, H., and Kenna, J. G. (2010) Risk assessment and mitigiation strategies for reactive metabolites in drug discovery and development Chem.-Biol. Interact. 192, 65-71
33. Lammert, C., Einarsson, S., Saha, C., Niklasson, A., Bjornsson, E., and Chalasani, N. (2008) Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals Hepatology 47, 2003-9
34. Hughes, J. D., Blagg, J., Price, D. A., Bailey, S., DeCrescenzo, G. A., Devraj, R. V., Ellsworth, E., Fobian, Y. M., Gibbs, M. E., Gilles, R. W., Greene, N., Huang, E., Krieger-Burge, T., Loesel, J., Wager, T., Whiteley, L., and Zhang, Y. (2008) Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18, 4872-4875
35. Rowland, M., Peck, C., and Tucker, G. (2011) Physiologically-based pharmacokinetics in drug development and regulatory science Annu. Rev. Pharmacol. Toxicol. 51, 45-73
36. Jones, H. M., Dickins, M., Youdim, K., Gosset, J. R., Attkins, N. J., Hay, T. L., Gurrell, I. K., Logan, Y. R., Bungay, P. J., Jones, B. C., and Gardner, I. B. (2012) Application of PBPK modelling in drug discovery and development at Pfizer Xenobiotica 42, 94-106
37. Fontana, E., Dansette, P. M., and Poli, S. M. (2005) Cytochrome P450 enzyme mechanism based inhibitors: common substructures and reactivity Curr. Drug Metab. 6, 413-54
38. Zimmerlin, A., Trunzer, M., and Faller, B. (2011) CYP3A Time-dependent inhibition risk assessment validated with 400 reference drugs Drug Metab. Dispos. 39, 1039-1046
39. Mulder, G. J and Le, C. T. (1988) A rapid, simple in vitro screening test, using [3H]glutathione and L-[35S]cysteine as trapping agents, to detect reactive intermediates of xenobiotics Toxicol. in Vitro 2, 225-30
40. Takakusa, H, Masumoto, H, Makino, C, Okazaki, O, and Sudo, K. (2009) Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione Drug Metab. Pharmacokinet. 24, 100-7
41. Rousu, T., Pelkonen, O., and Tolonen, A (2009) Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry Rapid Commun. Mass Spectrom. 2, 843-55
42. Gan, J., Harper, T. W., Hsueh, M. M., Qu, Q., and Humphreys, W. G. (2005) Dansyl glutathione as a trapping agent for the quantitative estimation and identification of reactive metabolites Chem. Res. Toxicol. 18, 896-903
43. Soglia, J. R., Harriman, S. P., Zhaoa, S., Barberia, J., Cole, M. J., Boud, J. G., and Contillo, L. G. (2004) The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent J. Pharm. Biomed. Anal. 36, 105-16
44. LeBlanc., A., Shiao, T. C., Roy, R., and Sleno, L. (2010) Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching Rapid Commun. Mass Spectrom. 24, 1241-50